Allurion Technologies
-
Devices & Diagnostics, Artificial Intelligence, BioPharma
Newly Public Allurion Aims to Show How Med Tech Can Complement Obesity Drugs
Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.
-
Weight Loss in a Pill Device Firm Allurion Heads to NYSE via SPAC Merger
Allurion Technologies has developed a gastric balloon that does not require surgery. The merger deal taking Allurion public comes as the company continues global commercialization of its technology.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Allurion raises $27M to commercialize gastric balloon device in the U.S. and beyond
The swallowable balloon eliminates the need for endoscopy and anesthesia, reducing costs for patients – who are generally paying out of pocket.
-
Devices & Diagnostics, Startups
Another startup hoping to tackle obesity using a device raises $19M
Allurion Technologies is seeking $27 million to bring its gastric balloon device, available in Europe, to the U.S. market to tackle the obesity epidemic.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
